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Kathryn B. Garber1,*Sometimes Self-Recognition Is a Bad Thing
Since a genome-wide association with type 1 diabetes
(T1D) was reported a few years ago, the R620W variant of
PTPN22 has reproducibly been associated with a range of
autoimmune disorders, particularly those with a strong
autoantibody component. This clued immunologists in
to the importance of this protein tyrosine phosphatase
nonreceptor in the regulation of the immune response.
Typically, there are a couple of checkpoints at which auto-
reactive B cells are eliminated from the body so that auto-
immunity can be avoided. Menard et al. recently found
that carriers of the PTPN22 autoimmunity risk variant
have deficits in their ability to get rid of developing autor-
eactive B cells, and this deficit leads to accumulation of
self-reactive mature B cells in the periphery. These experi-
ments were done in healthy individuals, and thus the pres-
ence of these autoreactive B cells precedes the develop-
ment of autoimmunity and could be an early step in the
process that leads to the development of disease. Individ-
uals with T1D or rheumatoid arthritis also have deficits
in the B cell tolerance checkpoints, whether or not they
carry the R620W allele, so apparently there are additional
genetic and/or environmental insults that feed into this
same pathway, the elucidation of which is likely to give
us targets for treatment.
Menard et al. (2011). J. Clin. Invest., 121, 3635–3644.Age Up, Recombination Down
Recombination is not simply a useful way of shuffling
genetic variation during sexual reproduction; the forma-
tion of the bivalents during meiosis ensures proper segre-
gation of homologous chromosomes. In the absence of
sufficient crossover events, there is a risk of nondisjunc-
tion. In a recent paper, Hussin et al. made use of genotype
data from a number of pedigrees to assess the effects of
parental age on recombination rates, and they report
decreasing rates of recombination with maternal age.
More notable reductions in recombination rates were
found in the middle of chromosome arms and at the sub-
telomeres. Although similar studies have found conflicting
results, it is tempting to correlate this reduction in recom-
bination with the increased risk of aneuploidy in the
offspring of older mothers.
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The AmericCommon Variation in FBN1 Is Associated
with Aortic Aneurysm
Although thoracic aortic aneurysm can occur as a domi-
nant trait, sometimes as part of a syndrome such as Mar-
fan, most cases are sporadic and idiopathic. Beyond the
known risk factors, which include hypertension and con-
genital cardiovascular abnormalities, little is known about
the etiology of these cases that seem to occur out of the
blue. A recent genome-wide association study made use
of three case samples of individuals who suffered from
thoracic aortic aneurysm and/or aortic dissection but
who had no evidence of syndromic disease or family
history. A single genomic locus reached genome-wide sig-
nificance, at chromosome 15q21.1. The associated SNPs
were in a large linkage disequilibrium block that contained
a single gene, FBN1, which is the gene mutated in Marfan
syndrome. Whereas haploinsufficiency for FBN1 leads
to Marfan syndrome, these data suggest that common
variation in the same gene contributes to the sporadic,
nonsyndromic forms of aortic aneurysm and dissection
and imply that the medications in clinical trials for Marfan
syndrome might be useful in treating sporadic forms of
aortic aneurysm.
LeMaire et al. (2011). Nature Genet. In Press. Published
online September 11, 2011. 10.1038/ng.934.Weighing the Balance between Normal
and Pathogenic Copy-Number Variation
The increased resolution of chromosomal microarrays
means that we can find a genetic explanation for a much
larger fraction of individuals with developmental and
intellectual disabilities than we ever could before. Yet,
not all copy-number variants (CNVs) are straightforward
to interpret. Two recent large studies, each with a dataset
of more than 15000 patients who had a variety of develop-
mental and intellectual disabilities that triggered genetic
testing, aimed to tackle this problem. For both studies,
the diagnostic yield, based on large CNVs, was approxi-
mately 14%. Kaminsky et al. used data from the ISCA
consortium and focused on the frequency of CNVs at 14
regions associated with recurrent rearrangements. A statis-
tical comparison with a set of more than 10,000 published
controls allowed them to gain better confidence in deter-
mining which CNVs are likely to be pathogenic. Cooperta, GA 30322, USA
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et al. analyzed a collection of samples from Signature
Genetics by using a sliding-window approach to compare
CNVs found in their cases to a set of more than 8000
controls. They define several novel or previously weakly
supported candidate pathogenic CNVs, including one at
15q25 that is presented in more detail. Together, the data
from these studies will allow certain CNVs to be reclassified
from ‘‘variants of unknown significance’’ to ‘‘likely to be
pathogenic’’; such CNVs include duplications at 16p11.2,
which were found by both groups to be heavily enriched
in cases compared to controls.
Kaminsky et al. (2011). Genet. Med., 13, 777–784.
Cooper et al. (2011). Nature Genet., 43, 838–846.
It’s a Phase
A major hole in the ability to interpret human genome
sequences is the fact that the sequences of the two copies
of each chromosome are not resolved, or phased. If you
find two sequence variants in a gene, this means you
cannot tell whether they are located on the same or484 The American Journal of Human Genetics 89, 483–485, Octoberdifferent copies of that gene, unless additional family
members are genotyped. In the context of medical
management, this can have major implications; for
example, it can determine whether somebody will be
affected by a recessive condition or be a carrier. Suk et al.
have constructed the most complete haplotype-resolved
genome to date through SOLiD sequencing of a fosmid
library from a healthy German male. They were able to
construct haplotype pairs for more than 80% of genes.
Of these, 89 putative disease-relevant genes contained
two or more predicted nonsynonymous SNPs. These
changes were in cis in 49 cases and in trans in 40, so this
phasing would be crucial to the interpretation of this
individual’s genome. The genome, dubbed Max Planck
One, is the beginning of a larger project aimed at assessing
individual haplotype architecture, and the data are publi-
cally available as tracks in the UCSC and Ensembl genome
browsers.
Suk et al. (2011). Genome Res. In Press. Published online
August 3, 2011. 10.1101/gr.125047.111This Month in Our Sister JournalsAre Schizophrenia CNVs Really Neuropsychiatric
CNVs?
It is not news that the same CNV can be found in individ-
uals with a range of neurological phenotypes. The classic
example is the 22q11 microdeletion syndrome, which
can cause, among other features, autism, seizure disorder,
and schizophrenia. What has been less clear is whether
this is the exception or the rule for CNVs across the
genome. Researchers from Signature Genomics tackled
this question by using data they have amassed from
whole-genome comparative-genomic-hybridization arrays
onmore than 38,000 individuals. They started with a set of
CNVs that had been previously implicated in schizo-
phrenia, and they mined their database to assess the range
of phenotypes associated with those CNVs . All 20 of the
previously published ‘‘schizophrenia’’ CNVs they exam-
ined, as well as six identified in patients referred for schizo-
phrenia in their study, were also found in patients with
a range of indications for the cytogenetic testing. The neu-
rodevelopmental indications ranged from autism to intel-
lectual disability to learning disabilities and beyond. As
the authors speculate, one could imagine that this broad
range of phenotypes results from the same underlying
CNV because the phenotypes lie on a spectrum and all
manifest the same underlying aberrant process. On the
other hand, a single CNV might comprise only part of
the underlying etiology of the phenotype, and its ultimate
outcome could be influenced by other genetic or environ-
mental insults. Whether either of these is the case willprobably be revealed as further individuals are assessed
for these CNVs and as people who were found to have
these CNVs as children get older and can be monitored
for the appearance of additional phenotypes, including
schizophrenia.
Sahoo et al. (2011). Genet. Med. In Press. 10.1097/
GIM.0b013e3182217a06.
How to Pick out the Truly Exceptional from the Rare
Although many successes have resulted from the deluge of
SNP-based genome-wide association studies that aimed to
identify common genetic variation to explain common
disease risk, we are left unable to fully explain a large
portion of the genetic contribution to these traits. One
thing these methods are not capable of detecting is the
contribution of rare variation to these traits. The advent
of next-generation sequencing technologies gives us the
genotyping capacity to look for rare genetic variation.
However, one can’t simply apply the same study designs
to the search for rare variants that influence disease risk.
Statistical methods that can detect these disease associa-
tions have been developed; most of them group variants
by gene location and analyze them together. One question
that remains is: What is the most effective study design for
the identification of rare variants that contribute to com-
plex traits? Ionita-Laza and Ottman compared designs
that use families versus unrelated individuals to detect an
enrichment of rare variants. To take into account the fact
that family members are more likely to share genetic7, 2011
variation in general than are unrelated individuals, they
used a correction factor for the number of variants
observed at a specific location on the basis of the degree
of relatedness of the individuals being compared. Their
analyses indicate that the optimal study design depends
on the sibling recurrence risk. When this value is low,The Americthe use of a sample of unrelated affected individuals who
have an affected family member is the most powerful
design. As the sibling recurrence risk increases, it becomes
more effective to use family-based designs.
Ionita-Laza & Ottman. (2011). Genetics. In Press. Published
online August 11, 2011, 10.1534/genetics.111.131813.an Journal of Human Genetics 89, 483–485, October 7, 2011 485
